Market Research Logo

Global Pharmerging Markets 2017-2021

Global Pharmerging Markets 2017-2021

About Pharmerging

The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

Technavio’s analysts forecast the global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.Covered in this report

The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

The market is divided into the following segments based on geography:

  • Tier 1
  • Tier 2
  • Tier 3
Technavio's report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Novartis
Other prominent vendors
  • Abbott Laboratories
  • AbbVie
  • Alexion Pharmaceuticals
  • Allergan
  • Amgen
  • Aspen
  • Astellas Pharma
  • Baxter
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • CSL Behring
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Eisai
  • Eli Lilly
  • Endo Health Pharmaceuticals
  • F. Hoffmann-La Roche
  • Fresenius
  • Gilead
  • Grifols
  • H. Lundbeck
  • Hospira
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Mallinckrodt Pharmaceuticals
  • Menarini
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Novo Nordisk
  • Otsuka
  • Shire
  • STADA Arzneimittel
  • Sun Pharmaceutical
  • Takeda Pharma
  • Teva Pharmaceutical Industries
  • UCB
  • Valeant Pharmaceuticals
Market driver
  • Limitations in developed economies fuels demand in emerging economies
  • For a full, detailed list, view our report
Market challenge
  • Stringent price control and generic -centric usage lead to value erosion
  • For a full, detailed list, view our report
Market trend
  • Potential of new countries in emerging markets
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
  • About Thoracic Surgery

    Thoracic surgery involves surgical treatment (open surgery or minimally invasive surgery) to address medical conditions involving the heart or lungs. It includes procedures such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. It is performed to treat end-stage heart failure, heart-lung transplants, and placement of ventricular-assist devices.

    Technavio’s analysts forecast the global thoracic surgery market to grow at a CAGR of 10.16% during the period 2016-2020.Covered in this report

    The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of medical devices required for thoracic surgeries.

    The market is divided into the following segments based on geography:
    • Americas
    • APAC
    • EMEA
    Technavio's report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    • Boston Scientific
    • Medtronic
    • Sorin
    • St. Jude Medical
    • Terumo
    Other prominent vendors
    • Abbott Vascular
    • Abiomed
    • AtriCure
    • Biosensors International
    • Biotronik
    • BioVentrix
    • C. R. Bard
    Market driver
    • Rise in incidence of cardiac disorders and increase in aging population
    • For a full, detailed list, view our report
    Market challenge
    • Potential complications associated with cardiac surgery
    • For a full, detailed list, view our report
    Market trend
    • Growing popularity of robot-assisted cardiac surgery
    • For a full, detailed list, view our report
    Key questions answered in this report
    • What will the market size be in 2020 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?


    Press Release

    Technavio Announces the Publication of its Research Report – Global Pharmerging Market 2017-2021

    Technavio recognizes the following companies as the key players in the global pharmerging market: AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, and Novartis

    Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, and Valeant Pharmaceuticals

    Commenting on the report, an analyst from Technavio’s team said: “Although the adoption of targeted therapies in emerging markets is low, it is expected to increase substantially during the forecast period, particularly in the long term. With the growing incidence of chronic diseases such as cancer, which requires specific therapies for the effective treatment, the adoption of targeted therapies is expected to witness substantial upward momentum. For instance, in India, the prevalence of cancer is expected to increase by 25%–40% in the next 10 years. The increasing awareness among physicians about the advantages of targeted therapies will certainly lead to an increase in adoption rates. Research studies done across the geographies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as lung cancer, breast cancer, chronic myeloid leukemia and lymphomas. Although, the cost of these targeted therapies is higher than the traditional ones, the growing awareness toward government subsidies and reimbursements could improve the adoption of such therapies even in the pharmerging nations. For instance, many states in India such as Gujarat, and Chattisgarh are providing such drugs at free of cost. Also, the leading players such as Novartis have implemented patient assistance programs to increase the affordability of Gleevec (a treatment for chronic myelogenous leukaemia) in India.”

    According to the report, the pharmaceutical market in developed economies has reached its maturity phase and hence, is witnessing stagnance in terms of growth. This is primarily due the unfavorable economic conditions and patent expiries of innovator products. In order to maintain a healthy growth trajectory, the companies started exploring for new sources of revenue. In addition, the healthcare budget cuts in developed markets such as the US, has further driven the vendors' focus toward emerging economies. For instance, in March 2016, the US government repealed the Affordable Care Act, which results in the shutdown of health insurance, and financial assistance for insurance. This plan would end the Medicaid expansion by eliminating the federal funding that earlier enabled to expand health coverage to millions of adults. Further, the plan would radically restructure the traditional Medicaid program leading to more than $1.8 trillion decline in healthcare spending. As these markets have largely been oriented to reimbursement structure, the patients are not comfortable with out of pocket scenario. Such radical cuts in healthcare expenditure hurts the growth of pharmaceutical vendors despite being defensive in nature, as patients/healthcare providers look for cheaper alternatives.

    Further, the report states that IP protection issues significantly influence the go-to-market strategies and tactics of the global pharmaceutical companies. For instance, the Indian government supports generic companies to provide end-users with affordable medication. The support is provided even when it goes against current patent laws and related rules of the World Trade Organization. For instance, Bayer HealthCare's Nexavar, a drug for hepatocellular carcinoma faces competition from Natco Pharma and due to the inability to afford the drug among the general population, the Indian government has given Natco, the manufacturing and marketing rights for the drug. Natco pays only 6% in royalties and is able to offer Nexavar approximately $170 per month, while Bayer HealthCare's Nexavar drug costs $5,500 per month. Bayer HealthCare eventually offered the drug at a reduced product price (almost 10% of original therapy costs), but on the condition that decreased prices are available only to those individuals diagnosed by licensed oncologists. The lack of proper guidelines for IP protection have fuelled the counterfeit products in emerging economies particularly in Africa. In Sub Saharan African countries, the share of counterfeit pharma drugs is close to 50%.

    Companies Mentioned

    AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi, Novartis, Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical Industries, UCB, Valeant Pharmaceuticals.

  • Executive summary
  • Scope of the report
    • Market overview
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Highlights
  • Global pharmaceutical market
    • Table Global country rankings in pharmaceutical market based on healthcare spending
    • Market size and forecast
      • Table Global pharmaceutical market 2016-2021 ($ trillions)
      • Table Drivers, challenges and trends of global pharmaceutical market
  • Road to pharmerging markets
    • Table Growth comparision between developed markets and pharmerging markets
  • Pharmerging markets
    • Table Share of pharmerging markets in global pharmaceutical market, 2016
  • Market landscape
    • Table Snapshot of key pharmerging markets
    • Table Regulatory landscape in key pharmerging markets
    • Table Pharmerging markets 2016-2021 ($ billions)
    • Medicine spending in emerging economies
      • Table Comparison of medicine spending in developed economies and pharmerging markets
      • Table Medicine spending and growth rates in pharmerging markets
      • Table Standard units in 2021 by product type in pharmerging countries
      • Table Expected medicine spending by geography
      • Table Volume growth and population with more than $5,000/year income by country 2016
      • Table Percentage share of pharmerging markets in global pharmaceutical market 2016-2021
      • Table Percentage share of tier I, II and III countries in total pharmerging markets 2016-2021
      • Table Pharmerging markets share by country, 2016
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by geography
    • Table Pharmerging markets segment by geography
  • Market overview of tier I countries
    • Table Geographic representation of tier I country
    • China
      • Table China GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
      • Table On-going healthcare reforms in China
      • Table Segmentation of Chinese pharmaceutical market
      • Table Segment analysis in Chinese pharmaceutical market
      • Table Regulatory bodies
      • Table Major therapy areas based on sales of drugs, 2016
      • Table Major acquisitions in Chinese pharmaceutical market 2014-2016
      • Table Drivers and challenges in Chinese pharmaceutical market
      • Table Pharmaceutical market in China 2016-2021 ($ billions)
      • Table China pharmaceutical market: SWOT analysis
  • Market overview of tier II countries
    • Table Geographic representation of tier II countries
    • Table Pharmaceutical market in tier II countries 2016-2021 ($ billions)
    • Brazil
      • Table Brazil GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
      • Table Regulatory bodies
      • Table Segmentation of pharmaceutical market in Brazil 2016
      • Table Major acquisitions in Brazil pharmaceutical market
      • Table Drivers and challenges in Brazilian pharmaceutical market
      • Table Pharmaceutical market in Brazil 2016-2021 ($ billions)
      • Table Brazil pharmaceutical market: SWOT analysis
    • Russia
      • Table Russia GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
      • Table Major acquisitions in Russian pharmaceutical market
      • Table Drivers and challenges in Russian pharmaceutical market
      • Table Pharmaceutical market in Russia 2016-2021 ($ billions)
      • Table Russia pharmaceutical market: SWOT analysis
    • India
      • Table India GDP 2011-2015 ($ trillions) and healthcare expenditure 2010-2014 (% of GDP)
      • Table Regulatory landscape
      • Table Major acquisitions in pharmaceutical sector in India
      • Table Drivers and challenges in Indian pharmaceutical market
      • Table Pharmaceutical market in India 2016-2021 ($ billions)
      • Table India pharmaceutical market: SWOT analysis
  • Market overview of tier III countries
    • Table Geographic representation of tier III countries
    • Market size and forecast
      • Table Pharmaceutical market in tier III countries 2016-2021 ($ billions)
      • Table Revenues from pharmaceuticals for few of the tier III countries 2016 ($ billions)
      • Table Snapshot of key countries in tier III countries
      • Table Tier III countries pharmaceutical market: SWOT analysis
  • Market drivers
    • Limitations in developed economies fuels demand in emerging economies
      • Table Factors that are driving the growth in emerging economies
    • Increasing focus toward biosimilar in potential areas
      • Table Biosimilar development in emerging economies
    • Expansion initiatives of vendors
      • Table Few acquisitions and their impact
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • IP protection issues
    • Socio-political issues in cross geography transactions
    • Stringent price control and generic-centric usage lead to value erosion
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Potential of new countries in emerging markets
    • Positive outlook toward adoption of targeted therapies
    • Evolving stakeholder landscape to change market dynamics
  • Vendor landscape
    • Competitive scenario
      • Table Positioning of key vendors in pharmerging markets 2015
      • Table Competitive analysis snapshot
  • Key vendor analysis
    • AstraZeneca
      • Table Top selling products in emerging markets 2015
      • Table Key takeaways
      • Table Key highlights in emerging markets
      • Table AstraZeneca strength assessment
      • Table Geographic segmentation by revenue 2015
    • GlaxoSmithKline
      • Table Key takeaways
      • Table Key highlights in emerging markets
      • Table GSK strength assessment
      • Table Geographic segmentation by revenue 2015
    • Pfizer
      • Table Key takeaways
      • Table Pfizer: YoY and growth rate in emerging markets
      • Table Segmentation by revenue in emerging markets ($ millions)
      • Table Key highlights in emerging markets
      • Table Pfizer strength assessment
      • Table Pfizer: Geographical segmentation by revenue 2015
    • Sanofi
      • Table Top selling products
      • Table Key emerging products
      • Table Geographical segmentation by revenue
      • Table Key takeaways
      • Table Key highlights in emerging markets
      • Table Sanofi strength assessment
    • Novartis
      • Table Key takeaways
      • Table Key highlights in emerging markets
      • Table Novartis strength assessment
      • Table Novartis: Geographical segmentation by revenue 2015
    • Other prominent vendors
  • Appendix
    • List of Abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report